Endometrial Cancer

  • Paolo Casadio
  • Giulia MagnarelliEmail author
  • Andrea Alletto
  • Francesca Guasina
  • Ciro Morra
  • Maria Rita Talamo
  • Mariangela La Rosa
  • Hsuan Su
  • Jessica Frisoni
  • Renato Seracchioli


Endometrial carcinoma is the most commonly diagnosed gynecologic malignancy. A complete understanding of the epidemiology, histopathology, diagnosis, and management for this type of cancer allows a correct identification of women at increased risk, facilitating early diagnosis and improving the overall survival. New diagnostic exams are available to assist the clinicians in evaluating women with abnormal uterine bleeding that is the most common presenting symptom of endometrial cancer. Early diagnosis is based on the histological evaluation of hysteroscopic endometrial samples. After correct diagnosis and preoperative evaluation, patients usually undergo surgical treatment including total hysterectomy and bilateral salpingo-oophorectomy with or without pelvic and para-aortic lymphadenectomy, according to cancer grade and stage. Radiotherapy and chemotherapy can be offered to improve the outcome of some patients. Nowadays an alternative hysteroscopic conservative treatment could be proposed to younger patients with diagnosis of early endometrioid adenocarcinoma. However more studies are necessary to standardize the conservative management.


Endometrium Cancer Hysteroscopy Conservative treatment Review 


  1. 1.
    Norton M, et al. Callen’s Ultrasonography in obstetrics and gynecology. 6th ed. Philadelphia, PA: Elsevier; 2017.Google Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54(1):8–29.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S105–43. (Level III).CrossRefGoogle Scholar
  5. 5.
    American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005;106:413–25.CrossRefGoogle Scholar
  6. 6.
    Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):257–66.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Kitchener HC, Trimble EL. Endometrial Cancer Working Group of the Gynecologic Cancer I. Endometrial cancer state of the science meeting. Int J Gynecol Cancer. 2009;19(1):134–40.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Dinkelspiel HE, Wright JD, Lewin SN, Herzog TJ. Contemporary clinical management of endometrial cancer. Obstet Gynecol Int. 2013;2013:583891.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA. Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. World Health Organization classification of tumours. Lyon, France: IARC Press; 2003. p. 221–32. (Level III).Google Scholar
  10. 10.
    American College of Obstetricians and Gynecologists. ACOG Committee Opinion, number 631, May 2015: Endometrial Intraepithelial Neoplasia. Society of Gynecologic Oncology.Google Scholar
  11. 11.
    American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 149, April 2015: Endometrial cancer. Obstet Gynecol. 125(4):1006–26.Google Scholar
  12. 12.
    American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician- gynecologists, number 128, July 2012: Diagnosis of abnormal uterine bleeding in reproductive aged women. Obstet Gynecol. 120:197–206.Google Scholar
  13. 13.
    Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642–6. (Level III).PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260–7. (Level II-3).PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797–806. (Level II-3).PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Rabban JT, Zaloudek CJ. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis. Pathology. 2007;39:125–33. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 1991;40:207–17. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    National Institute for Health and Care Excellence. NICE guideline,14 March 2018. Heavy menstrual bleeding: assessment and management (NG 88).
  19. 19.
    Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 2001;80:1131.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. Am J Obstet Gynecol. 1988;158:489.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA. 2002;288:1610–21.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Gkrozou F, Dimakopoulos G, Vrekoussis T, et al. Hysteroscopy in women with abnormal uterine bleeding: a meta-analysis on four major endometrial pathologies. Arch Gynecol Obstet. 2015;291:1347–54.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Ianieri MM, Staniscia T, Pontrelli G, Di Spiezio SA, Manzi FS, Recchi M, et al. A new hysteroscopic risk scoring system for diagnosing endometrial hyperplasia and adenocarcinoma. J Minim Invasive Gynecol. 2016;23(5):712–8.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Mencaglia L, Cavalcanti de Albuquerque Neto L, Arias Alvarez RA. Manual of hysteroscopy—diagnostic, operative and office hysteroscopy. Endo: Press Tuttlingen, Germany; 2011.Google Scholar
  25. 25.
    De Marchi F, Fabris AM, Tommasi L, Nappi L, Saccardi C, Litta P. Accuracy of hysteroscopy made by young residents in detecting endometrial pathologies in postmenopausal women. Eur J Gynaecol Oncol. 2014;35:219–23.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Gasparri F, Scarselli G, Colafranceschi M, Taddei G, Tantini C, Savino L. Management of precancerous lesions of the endometrium. Proceedings of the eleventh world congress of obstetrics and gynecology. In: Ludwig H, Thomsen K, editors. Gynaecology and obstetrics. Berlin: Springer-Verlag; 1986.Google Scholar
  27. 27.
    Gabrielli S, Marabini A, Bevini M, et al. Transvaginal sonography vs. hysteroscopy in the preoperative staging of endometrial carcinoma. Ultrasound Obstet Gynecol. 1996;7:443–6.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Bettocchi S, Ceci O, Vicino M, Marello F, Impedovo L, Selvaggi L. Diagnostic inadequacy of dilatation and curettage. Fertil Steril. 2001;75:803–5.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Deffieux X, Gauthier T, Menager N, Legendre G, Agostini A, Pierre F, et al. Hysteroscopy: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians. Eur J Obstet Gynecol Reprod Biol. 2014;178:114.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    AIOM, Linee guida Neoplasie dell’utero: endometrio e cervice; 2015.Google Scholar
  31. 31.
    Manfredi R, Mirk P, et al. Loco-regional staging of endometrial carcinoma: role of MR imaging in predicting surgical staging. Radiology. 2004;231:372–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Suga T, Nakamoto Y, et al. Clinical value of FDG-PET for preoperative evaluation of endometrial cancer. Ann Nucl Med. 2011;25(4):269–75. Epub 2011 Mar 9.PubMedCrossRefGoogle Scholar
  33. 33.
    Signorelli M, Guerra L, et al. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases. Gynecol Oncol. 2009;115(2):231–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Saga T, Higashi T, et al. Clinical value of FDG-PET in the follow up of postoperative patients with endometrial cancer. Ann Nucl Med. 2003;17:197–203.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Rungruang B, Olawaiye AB. Comprehensive surgical staging for endometrial cancer. Rev Obstet Gynecol. 2012;5(1):28–34.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008;109:11–8.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Abu-Rustum NR, Gomez JD, Alektiar KM, et al. The incidence of isolated para-aortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol. 2009;15:236–8.CrossRefGoogle Scholar
  38. 38.
    DS MM, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecologic Oncology Group. Gynecol Oncol. 2007;105:508–16. (Level III).CrossRefGoogle Scholar
  39. 39.
    Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol. 1998;148:234–40. (Level II-2).PubMedCrossRefGoogle Scholar
  40. 40.
    Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension. 1999;34:320–5. (Level II-2).PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Todo Y, Kato H, Kaneucki M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375:1165–72.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Wilson TO, Podratz KC, Gaffey TA, et al. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol. 1990;162:418–23. discussion 423–426.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Mariani A, El-Nashar SA, Dowdy SC. Lymphadenectomy in endometrial cancer: which is the right question? Int J Gynecol Cancer. 2010;20(11 suppl 2):S52–4.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Pecorelli S. Revised FIGO staging for endometrium. Int J Gynecol Obstet. 2009;105(2):103–4.CrossRefGoogle Scholar
  45. 45.
    Edge SB, Byrd DR, Compton CC, et al., editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  46. 46.
    Janda M, Gebski V, Brand A, Hogg R, Jobling TW, Land R, et al. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncol. 2010;11:772–80. (Level I).PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study [published erratum appears in J Clin Oncol 2010;28:2805]. J Clin Oncol. 2009;27:5337–42. (Level I).PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27:5331–6. (Level I).PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Palomba S, Falbo A, Mocciaro R, Russo T, Zullo F. Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs). Gynecol Oncol. 2009;112:415–21. (Meta-analysis).PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Palomba S, Falbo A, Russo T, Zullo F. Updating of a recent meta-analysis of randomized controlled trials to assess the safety and the efficacy of the laparoscopic surgery for treating early stage endometrial cancer. Gynecol Oncol. 2009;114:135–6. (Meta-analysis).PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Lim PC, Kang E, Park do H. A comparative detail analysis of the learning curve and surgical outcome for robotic hysterectomy with lymphadenectomy versus laparoscopic hysterectomy with lymphadenectomy in treatment of endometrial cancer: a case-matched controlled study of the first one hundred twenty two patients. Gynecol Oncol. 2011;120:413–8. (Level II-3).PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, et al. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol. 2008;199:360.e1–9. (Level II-3).CrossRefGoogle Scholar
  53. 53.
    Coronado PJ, Herraiz MA, Magrina JF, Fasero M, Vidart JA. Comparison of perioperative outcomes and cost of robotic-assisted laparoscopy, laparoscopy and laparotomy for endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2012;165:289–94. (Level II-3).PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Gaia G, Holloway RW, Santoro L, Ahmad S, Di Silverio E, Spinillo A. Robotic-assisted hysterectomy for endometrial cancer compared with traditional laparoscopic and laparotomy approaches: a systematic review. Obstet Gynecol. 2010;116:1422–31. (Meta-analysis).PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56:419–27. (Level I).PubMedPubMedCentralGoogle Scholar
  56. 56.
    Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. ASTEC/EN.5 Study Group. Lancet. 2009;373:137–46. (Meta-analysis).PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology Group [published erratum appears in Gynecol Oncol 2004;94:241–2]. Gynecol Oncol. 2004;92:744–51. (Level I).PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. PORTEC Study Group. Gynecol Oncol. 2003;89:201–9. (Level I).PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. PORTEC Study Group. Lancet. 2010;375:816–23. (Level I).PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium [published erratum appears in Int J Gynaecol Obstet 2010;108:176]. Int J Gynaecol Obstet. 2009;105:103–4. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000;78:85–91. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol. 1997;67:56–60. (Level II-3).PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Goff BA, Goodman A, Muntz HG, Fuller AF Jr, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol. 1994;52:237–40. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Campagnutta E, Giorda G, De Piero G, Sopracordevole F, Visentin MC, Martella L, et al. Surgical treatment of recurrent endometrial carcinoma. Cancer. 2004;100:89–96. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Awtrey CS, Cadungog MG, Leitao MM, Alektiar KM, Aghajanian C, Hummer AJ, et al. Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol. 2006;102:480–8. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol. 1999;75:99–102. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118:14–8. (Meta-analysis).PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:543–52. (Level I).PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Geller MA, Ivy J, Dusenbery KE, Ghebre R, Isaksson Vogel R, Argenta PA. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the “sandwich” method for high risk endometrial carcinoma. Gynecol Oncol. 2010;118:19–23. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Geller MA, Ivy JJ, Ghebre R, Downs LS Jr, Judson PL, Carson LF, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol. 2011;121:112–7. (Level III).PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Onda T, Yoshikawa H, Mizutani K, Mishima M, Yokota H, Nagano H, et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer. 1997;75:1836–41.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Sovak MA, Hensley ML, Dupont J, Ishill N, Alektiar KM, Abu-Rustum N, et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol Oncol. 2006;103:451–7. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Hidaka T, Nakamura T, Shima T, Yuki H, Saito S. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. J Obstet Gynaecol Res. 2006;32:330–7. (Level III).PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Marnitz S, Köhler C, Gharbi N, Kunze S, Jablonska K, Herter J. Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions? Strahlenther Onkol. 2018;194:965–74.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:10–4. (Level II-3PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209–62.PubMedCrossRefGoogle Scholar
  77. 77.
    Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, Kapp DS, Osann K, Chan JK. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109:655–62.PubMedCrossRefGoogle Scholar
  78. 78.
    Duska LR, et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83:388–93.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol. 1998;91:349–54.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Cancer. 1997;79:320–7.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010;28:81–90.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer. 2000;7:227–42.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, Koupolovic J, Ben-Baruch G. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003;102:718.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95:133–8.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Liou W-S, Yap OWS, Chan JK, Westphal LM. Innovations in fertility preservation for patients with gynecologic cancers. Fertil Steril. 2005;84:1561–73.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Yahata T, Fujita K, Aoki Y, Tanaka K. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod. 2006;21:1070–5.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017;28(1):e2.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Kesterson JP, et al. Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls. Gynecol Oncol. 23(2):120–4. Scholar
  89. 89.
    US Food & Drug Administration (FDA). Mirena (levonorgestrel-releasing intrauterine system) [Internet]. Silver Spring, MD: FDA; c2009. [cited 2012 Mar 1]. Available from
  90. 90.
    Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol. 2018;25(2):308–13.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Chiva L, Lapuente F, González-Cortijo L, Carballo N, García JF, Rojo A, Gonzalez-Martín A. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol. 2008;111:S101–4.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Gunderson CC, Fader AN, Carson KA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125:477–82.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95:133–8.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Royal College of Obstetricians and Gynecologist. Management of Endometrial Hyperplasia. RCOG/BSGE Green-top Guidelines, No.167, February 2016.Google Scholar
  95. 95.
    Gusberg SB, Kaplan AL. Precursors of corpus cancer: IV. Adenomatous hyperplasia as stage o carcinoma of the endometrium. Am J Obstet Gynecol. 1963;87:662–78.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol. 2000;190:462–9.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? Gynecol Oncol. 2000/2003;76:287–90.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Mutter GL, Kauderer J, Baak JP, Alberts D, Gynecologic Oncology Group. Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. Hum Pathol. 2008;39:866–74.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93:1286–9.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Di Spiezio SA, Mazzon I, Gargano V, Di Carlo C, Guida M, Mignogna C, Bifulco G, Nappi C. Hysteroscopic treatment of atypical polypoid adenomyoma diagnosed incidentally in a young infertile woman. Fertil Steril. 2008;89:456.e9–12.Google Scholar
  101. 101.
    Casadio P, et al. Fertility-sparing treatment of endometrial cancer with initial infiltration of myometrium by resectoscopic surgery: a pilot study. Oncologist. 2018;23:478–80.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Paolo Casadio
    • 1
  • Giulia Magnarelli
    • 1
    Email author
  • Andrea Alletto
    • 1
  • Francesca Guasina
    • 2
  • Ciro Morra
    • 1
  • Maria Rita Talamo
    • 1
  • Mariangela La Rosa
    • 1
  • Hsuan Su
    • 3
  • Jessica Frisoni
    • 4
  • Renato Seracchioli
    • 1
  1. 1.Department of Gynaecology and Physiopathology of ReproductionS. Orsola-Malpighi Hospital, University of BolognaBolognaItaly
  2. 2.Obstetrics and Gynaecological DepartmentSanta Chiara HospitalTrentoItaly
  3. 3.Division of Gynaecologic Endoscopy, Department of Obstetrics and GynaecologyChang Gung Memorial Hospital at Linkou Chang, Gung University School of MedicineTao-YuanTaiwan
  4. 4.Department of Experimental, Diagnostic and Speciality Medicine (DIMES)Alma Mater Studiorum, University of BolognaBolognaItaly

Personalised recommendations